UNSPSC 51412015: Mefenidil fumarate

This classification denotes a vasodilating agent C12H11N3.C4H2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5QH19BF6YG, chemically known as 1h-imidazole-4-acetonitrile, 5-methyl-2-phenyl-, (e)-2-butanedioate (1:1), but more generally known as mefenidil fumarate, which bears US NIH Compound Identifier 18177393. Most nations, for tariff and trade purposes, schedule mefenidil fumarate under HS 29332990 and SITC 51573. As of Q4 2014, MEFENIDIL FUMARATE remains US FDA's Preferred Term for this commodity.

Mefenidil fumarate bears US NLM identifiers UMLS ID C1881763 and NCI Concept Code C66073. SMILES: CC1C(NC([NH]1)C2CCCCC2)CC#N.C(=C/C(=O)[O-])\C(=O)[O-].

UNSPSC 51412015 Mefenidil fumarate (Commodity) represents a narrow pharmaceutical line item — a specific cardiovascular medication — that state and local governments procure as part of broader emergency medical services medication supplies and pharmacy benefit programs. State and local buyers do not typically solicit this drug in isolation; instead, they source it as one component within larger advanced life support medication contracts or multi-source generic pharmaceutical cooperative agreements serving healthcare delivery, emergency response, and employee health benefit programs. The issuing bodies include city purchasing departments managing fire and rescue operations, state health and human services commissions overseeing pharmacy benefits, and multistate cooperative purchasing alliances aggregating demand across state and local member agencies. Work under this code involves supplying pharmaceutical products meeting FDA manufacturing and supply-chain security standards, maintaining specified shelf life and expiration timelines, arranging logistics and pickup of expired stock, and complying with accessibility, hazard-communication, and insurance documentation requirements.

Geographic activity spans Florida, Texas, Minnesota, and Oregon based on recent solicitation posting. The City of Tampa's Purchasing Department released an IFB (Bid No. 26-P-00188) on April 24, 2026, seeking advanced life support medications including Epinephrine, Labetalol, Adenosine, and Diltiazem for Tampa Fire Rescue, with a firm response deadline of April 8, 2026, and an estimated contract value of $40,000.00; the award carries a one-year base term plus renewal options and unilateral extension provisions, and includes a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount not to exceed $10,000. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs for a future Therapeutic Pharmacy Initiative, reflecting preliminary procurement planning rather than current active demand. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, specifying supply through three authorized wholesalers effective July 1, 2026, and covering participating state and local facilities across Minnesota and Oregon; evaluation weights 75 percent on price competitiveness, with contract terms of two years for new responders and extensions at MMCAP's discretion.